Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging Study of 89Zr-S095012 in Advanced Solid Tumours
NCT05638334Phase 1Terminated
- Sponsor
- Servier
- Start
- Nov 2022
- Primary completion
- Jun 2024
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PRS-344 in solid tumor (advanced stage), sponsored by Servier. Primary endpoints: Change in Positron Emission Tomography/Computed Tomography scan images, Parameters derived from PET scans for organs and tumour lesions and 3 more. Started Nov 2022; status: terminated.
02
Drugs
PRS-344
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05638334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638334.